Dyno Therapeutics

Dyno Therapeutics is a biotechnology company based in Watertown, Massachusetts, founded in 2018.

The company specializes in gene therapy, focusing on engineering Adeno-Associated Virus (AAV) capsids using advanced artificial intelligence and machine learning techniques. Dyno's mission is to enhance in vivo gene delivery, aiming to improve the lives of patients through innovative genetic technologies. The cornerstone of Dyno's offerings is the CapsidMap Platform, which utilizes AI to optimize AAV capsid vectors for various therapeutic applications, including ophthalmology, muscle disorders, and central nervous system diseases. Dyno provides custom AAV engineering, optimization services, and licensing of its AI-designed capsids to pharmaceutical and biotechnology companies. The company has established partnerships with major healthcare firms like Roche and Novartis, contributing to significant advancements in gene therapy development. With a strong focus on expanding its capabilities, Dyno Therapeutics is poised to play a vital role in the future of genetic medicine.